ANEW Medical Files S-1 Registration
Ticker: GRMLW · Form: S-1 · Filed: Sep 5, 2024 · CIK: 1907223
Sentiment: neutral
Topics: sec-filing, s-1, ipo-readiness
TL;DR
ANEW Medical (fka Redwoods Acquisition) filed S-1, get ready for potential IPO.
AI Summary
ANEW Medical, Inc. has filed an S-1 registration statement with the SEC. The company, formerly known as Redwoods Acquisition Corp. until January 27, 2022, is incorporated in Delaware and operates in the Biological Products sector. Its principal executive offices are located at 13576 Walnut Street, Suite A, Omaha, NE 68144, with a business phone number of (833) 931-6330.
Why It Matters
This S-1 filing indicates ANEW Medical, Inc. is preparing to offer securities to the public, which could lead to significant changes in its capital structure and market presence.
Risk Assessment
Risk Level: medium — S-1 filings are typically associated with initial public offerings or significant secondary offerings, which inherently carry market and execution risks.
Key Numbers
- 2836 — SIC Code (Primary Standard Industrial Classification Code for Biological Products)
- 86-2727441 — IRS Number (Registrant's Employer Identification Number)
Key Players & Entities
- ANEW Medical, Inc. (company) — Registrant
- Redwoods Acquisition Corp. (company) — Former company name
- 20220127 (date) — Date of name change
- 13576 Walnut Street, Suite A Omaha, NE 68144 (address) — Principal executive offices
- (833) 931-6330 (phone_number) — Business phone number
- Joseph A. Sinkule (person) — Agent for service
- Paul Goodman, Esq. (person) — Correspondence contact
- Cyruli Shanks & Zizmor, LLP (company) — Legal counsel
- 420 Lexington Avenue Suite 2320 New York, NY 10170 (address) — Legal counsel address
- (212) 212-6800 (phone_number) — Legal counsel phone number
FAQ
What is the purpose of this S-1 filing for ANEW Medical, Inc.?
The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.
When did ANEW Medical, Inc. change its name from Redwoods Acquisition Corp.?
The company changed its name from Redwoods Acquisition Corp. on January 27, 2022.
Where are ANEW Medical, Inc.'s principal executive offices located?
The principal executive offices are located at 13576 Walnut Street, Suite A, Omaha, NE 68144.
Who is listed as the agent for service for ANEW Medical, Inc.?
Joseph A. Sinkule is listed as the agent for service, with his address and telephone number matching the company's principal executive offices.
What is the Standard Industrial Classification (SIC) code for ANEW Medical, Inc.?
The primary SIC code listed is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 4,454 words · 18 min read · ~15 pages · Grade level 18.1 · Accepted 2024-09-05 12:31:49
Key Financial Figures
- $0.0001 — 7,925 shares of common stock, par value $0.0001 per share, of ANEW Medical Inc. These s
- $0.95 — w sales prices of our common shares was $0.95 per share. These prices will fluctuate
Filing Documents
- ea0213401-s1_anewmedical.htm (S-1) — 1706KB
- ea021340101ex5-1_anewmedi.htm (EX-5.1) — 7KB
- ea021340101ex23-2_anewmedi.htm (EX-23.2) — 3KB
- ea021340101ex-fee_anewmedi.htm (EX-FILING FEES) — 13KB
- image_001.jpg (GRAPHIC) — 43KB
- fin_001.jpg (GRAPHIC) — 18KB
- fin_002.jpg (GRAPHIC) — 12KB
- 0001213900-24-075939.txt ( ) — 4961KB
- wena-20240630.xsd (EX-101.SCH) — 34KB
- wena-20240630_cal.xml (EX-101.CAL) — 23KB
- wena-20240630_def.xml (EX-101.DEF) — 159KB
- wena-20240630_lab.xml (EX-101.LAB) — 305KB
- wena-20240630_pre.xml (EX-101.PRE) — 167KB
- ea0213401-s1_anewmedical_htm.xml (XML) — 404KB
Financial Statements
Financial Statements F-1 Unless otherwise specified or the context otherwise requires, references in this prospectus to "we", "our" and "us" and the "Company" refer to ANEW Medical, Inc. i PROSPECTUS SUMMARY To understand this offering fully, you should read the entire prospectus carefully, including the risk factors beginning on page 2 and the consolidated financial statements. This summary highlights selected information appearing elsewhere in this prospectus. While this summary highlights what we consider to be important information about us, you should carefully read this entire prospectus before investing in our Common Stock, especially the risks and other information we discuss under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our consolidated financial statements and related notes beginning on page 60. Our fiscal year end is December 31 and our fiscal years ended December 31, 2023 and 2022 are sometimes referred to herein as fiscal years 2023 and 2022, respectively. Some of the statements made in this prospectus discuss future events and developments, including our future strategy and our ability to generate revenue, income and cash flow. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those contemplated in these forward-looking statements. See "Forward-Looking the "Company" or "our Company" or "ANEW" refer to ANEW Medical, Inc, a Delaware corporation, and our each of our subsidiaries. Issuer: ANEW Medical, Inc., a Delaware corporation. Shares of Common Stock offered by the Selling Stockholders (1): 10,027,925 Shares of Common Stock Outstanding Prior to the Offering (1) 21,263,515 Terms of Offering The Selling Stockholders will determine when and how they will sell shares o